Using kinase inhibitors, such as midostaurin, to treat acute myeloid leukemia typically only produces a partial response. Mark Levis, MD, PhD, from The Johns Hopkins Hospital, Baltimore, MD, discusses why this is the case at the International Conference on Acute Myeloid Leukemia 2017 in Estoril, Portugal by the European School of Hematology (ESH). Dr Levis also highlights the challenges that current clinical trials of these inhibitors are trying to address.
The challenges of using kinase inhibitors for AML treatment
